Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles

Chia Chyi Liu, Meng Shin Guo, Shang-Rung Wu, Hsiao Yu Lin, Ya Ting Yang, Wei Chih Liu, Yen Hung Chow, Dar-Bin Shieh, Jen-Ren Wang, Pele Chong

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Childhood exanthema caused by different serotypes of coxsackievirus (CV-A) and enterovirus A71 (EV-A71) has become a serious global health problem; it is commonly known as hand, foot, and mouth disease (HFMD). Current EV-A71 vaccine clinical trials have demonstrated that human antibody responses generated by EV-A71 vaccinations do not cross-neutralize coxsackievirus A16 (CV-A16). An effective multivalent HFMD vaccine is urgently needed. From molecular epidemiological studies in Southeast Asia, CV-A6 and CV-A10 are commonly found in HFMD outbreaks. In this study, CV-A6 and CV-A10 were individually cultured in rhabdomyosarcoma (RD) cells grown in medium containing serum, harvested and concentrated. In viral downstream purification, two viral fractions were separated by sucrose gradient zonal ultracentrifugation and detected using a SDS-PAGE analysis and a virus infectivity assay. These two viral fractions were formalin-inactivated, and only the infectious particle fraction was found to be capable of inducing CV-A serotype-specific neutralizing antibody responses in animal immunogenicity studies. These mouse and rabbit antisera also failed to cross-neutralize EV-A71 and CV-A16 infections. Only a combination of formalin-inactivated EV-A71, CV-A6, CV-A10 and CV-A16 multivalent vaccine candidates elicited cross-neutralizing antibody responses in both mouse and rabbit immunogenicity studies. The current results certainly provide important information for multivalent HFMD vaccine development.

Original languageEnglish
Pages (from-to)58-66
Number of pages9
JournalAntiviral Research
Volume129
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Enterovirus
antineoplaston A10
Virion
Hand, Foot and Mouth Disease
Vaccines
Antibody Formation
Neutralizing Antibodies
Formaldehyde
Coxsackievirus Infections
Rabbits
Southeastern Asia
Rhabdomyosarcoma
Ultracentrifugation
Exanthema
Disease Outbreaks
Sucrose
Immune Sera
Epidemiologic Studies
Polyacrylamide Gel Electrophoresis
Vaccination

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

Cite this

Liu, Chia Chyi ; Guo, Meng Shin ; Wu, Shang-Rung ; Lin, Hsiao Yu ; Yang, Ya Ting ; Liu, Wei Chih ; Chow, Yen Hung ; Shieh, Dar-Bin ; Wang, Jen-Ren ; Chong, Pele. / Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. In: Antiviral Research. 2016 ; Vol. 129. pp. 58-66.
@article{bf5941f1dac94cbdb4d6ce7289cf5ddf,
title = "Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles",
abstract = "Childhood exanthema caused by different serotypes of coxsackievirus (CV-A) and enterovirus A71 (EV-A71) has become a serious global health problem; it is commonly known as hand, foot, and mouth disease (HFMD). Current EV-A71 vaccine clinical trials have demonstrated that human antibody responses generated by EV-A71 vaccinations do not cross-neutralize coxsackievirus A16 (CV-A16). An effective multivalent HFMD vaccine is urgently needed. From molecular epidemiological studies in Southeast Asia, CV-A6 and CV-A10 are commonly found in HFMD outbreaks. In this study, CV-A6 and CV-A10 were individually cultured in rhabdomyosarcoma (RD) cells grown in medium containing serum, harvested and concentrated. In viral downstream purification, two viral fractions were separated by sucrose gradient zonal ultracentrifugation and detected using a SDS-PAGE analysis and a virus infectivity assay. These two viral fractions were formalin-inactivated, and only the infectious particle fraction was found to be capable of inducing CV-A serotype-specific neutralizing antibody responses in animal immunogenicity studies. These mouse and rabbit antisera also failed to cross-neutralize EV-A71 and CV-A16 infections. Only a combination of formalin-inactivated EV-A71, CV-A6, CV-A10 and CV-A16 multivalent vaccine candidates elicited cross-neutralizing antibody responses in both mouse and rabbit immunogenicity studies. The current results certainly provide important information for multivalent HFMD vaccine development.",
author = "Liu, {Chia Chyi} and Guo, {Meng Shin} and Shang-Rung Wu and Lin, {Hsiao Yu} and Yang, {Ya Ting} and Liu, {Wei Chih} and Chow, {Yen Hung} and Dar-Bin Shieh and Jen-Ren Wang and Pele Chong",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.antiviral.2016.02.008",
language = "English",
volume = "129",
pages = "58--66",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. / Liu, Chia Chyi; Guo, Meng Shin; Wu, Shang-Rung; Lin, Hsiao Yu; Yang, Ya Ting; Liu, Wei Chih; Chow, Yen Hung; Shieh, Dar-Bin; Wang, Jen-Ren; Chong, Pele.

In: Antiviral Research, Vol. 129, 01.05.2016, p. 58-66.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles

AU - Liu, Chia Chyi

AU - Guo, Meng Shin

AU - Wu, Shang-Rung

AU - Lin, Hsiao Yu

AU - Yang, Ya Ting

AU - Liu, Wei Chih

AU - Chow, Yen Hung

AU - Shieh, Dar-Bin

AU - Wang, Jen-Ren

AU - Chong, Pele

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Childhood exanthema caused by different serotypes of coxsackievirus (CV-A) and enterovirus A71 (EV-A71) has become a serious global health problem; it is commonly known as hand, foot, and mouth disease (HFMD). Current EV-A71 vaccine clinical trials have demonstrated that human antibody responses generated by EV-A71 vaccinations do not cross-neutralize coxsackievirus A16 (CV-A16). An effective multivalent HFMD vaccine is urgently needed. From molecular epidemiological studies in Southeast Asia, CV-A6 and CV-A10 are commonly found in HFMD outbreaks. In this study, CV-A6 and CV-A10 were individually cultured in rhabdomyosarcoma (RD) cells grown in medium containing serum, harvested and concentrated. In viral downstream purification, two viral fractions were separated by sucrose gradient zonal ultracentrifugation and detected using a SDS-PAGE analysis and a virus infectivity assay. These two viral fractions were formalin-inactivated, and only the infectious particle fraction was found to be capable of inducing CV-A serotype-specific neutralizing antibody responses in animal immunogenicity studies. These mouse and rabbit antisera also failed to cross-neutralize EV-A71 and CV-A16 infections. Only a combination of formalin-inactivated EV-A71, CV-A6, CV-A10 and CV-A16 multivalent vaccine candidates elicited cross-neutralizing antibody responses in both mouse and rabbit immunogenicity studies. The current results certainly provide important information for multivalent HFMD vaccine development.

AB - Childhood exanthema caused by different serotypes of coxsackievirus (CV-A) and enterovirus A71 (EV-A71) has become a serious global health problem; it is commonly known as hand, foot, and mouth disease (HFMD). Current EV-A71 vaccine clinical trials have demonstrated that human antibody responses generated by EV-A71 vaccinations do not cross-neutralize coxsackievirus A16 (CV-A16). An effective multivalent HFMD vaccine is urgently needed. From molecular epidemiological studies in Southeast Asia, CV-A6 and CV-A10 are commonly found in HFMD outbreaks. In this study, CV-A6 and CV-A10 were individually cultured in rhabdomyosarcoma (RD) cells grown in medium containing serum, harvested and concentrated. In viral downstream purification, two viral fractions were separated by sucrose gradient zonal ultracentrifugation and detected using a SDS-PAGE analysis and a virus infectivity assay. These two viral fractions were formalin-inactivated, and only the infectious particle fraction was found to be capable of inducing CV-A serotype-specific neutralizing antibody responses in animal immunogenicity studies. These mouse and rabbit antisera also failed to cross-neutralize EV-A71 and CV-A16 infections. Only a combination of formalin-inactivated EV-A71, CV-A6, CV-A10 and CV-A16 multivalent vaccine candidates elicited cross-neutralizing antibody responses in both mouse and rabbit immunogenicity studies. The current results certainly provide important information for multivalent HFMD vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=84959339629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959339629&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2016.02.008

DO - 10.1016/j.antiviral.2016.02.008

M3 - Article

C2 - 26899790

AN - SCOPUS:84959339629

VL - 129

SP - 58

EP - 66

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -